Xolair® is a propriety name of omalizumab, a humanized monoclonal antibody that is engineered to bind to IgE, an allergic antibody, thus, decreases overall allergic reaction in the body. It is approved by the FDA since 2003 to use in patient 12 years and older with moderate to severe asthma who has failed conventional treatment. Recently in March 2014, it is approved for treating patients with recalcitrant chronic urticaria who continue to have hives despite being treated with several other conventional medications. For more information, please visit the official Xolair® website.

Back to main menu

Disclaimer